Effect of myricetin on cognitive impairments in the transgenic Drosophila model of Parkinson’s Disease by Ara, Gulshan et al.
Indian Journal of Experimental Biology 
Vol. 60, January 2022, pp. 27-33 
Effect of myricetin on cognitive impairments in the transgenic Drosophila 











 & Yasir Hasan Siddique
1
 
1Section of Genetics, Department of Zoology, Faculty of Life Sciences; 2Department of Chemistry, Faculty of Science, 
Aligarh Muslim University (AMU), Aligarh-202 002, Uttar Pradesh, India 
Received 11 March 2020; revised 10 April 2021 
Parkinson’s Disease (PD) is a progressive neurodegenerative disorder involving the loss of dopaminergic neurons. 
Despite the availability of many drugs to ease the life of PD patients, there is no permanent cure until now. Now-a-days, 
there has been a considerable attention towards the use of herbal products to treat PD patients worldwide due to less side 
effects. In this context, here we investigated myricetin, a common plant derived flavonoid, on the cognitive impairments 
exhibited by the transgenic Drosophila expressing human -synuclein in the neurons. The PD flies were allowed to feed on 
the diet having 10, 20 and 40 µM of myricetin for 24 days and then assayed for cognitive impairments. The exposure of 
myricetin showed a dose dependent significant delay in the cognitive impairments. Molecular docking studies showed the 
positive interaction between myricetin and -synuclein. The results suggest a protective effect of myricetin against the 
cognitive impairments.  
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Parkinson’s Disease (PD) is a progressive 
neurodegerative disease which results mainly due to 
the loss of dopaminergic neurons in the mid brain
1
. It 
is mainly characterized by the resting tremor, 
bradykinesia and rigidity. The drug therapy in PD is 
effective only in the early stages of the disease and is 




Substantial evidences suggest that the aggregation of 
alpha synuclein and the formation of Lewy bodies 
(LBs) is the crucial step in the progression of the 
disease
3
. To date, there is no preventive therapy for 
PD. A recent study on herbal resources to treat PD 
suggests that the compounds which could slow down 
or prevent aggregation and fibrillation of α-synuclein 
could act as a possible therapeutic agent
1
.  
Myricetin belongs to the flavonoid class of 
polyphenolic compounds, which possess antioxidant 
properties
4
. It is commonly found in vegetables, fruits, 
nuts, berries, tea and is also a part of red wine. 
Myricetin exhibit structural similarity with fisetin, 
luteolin, and quercetin and is reported to have similar 
functions as other members of the flavonol class of 
flavonoids
5
. In the present study, we investigated the 
effect of myricetin on the cognitive impairments 
being exhibited in transgenic flies. In the past few 
years, small organic molecules, especially certain 
polyphenolic compounds, have been extensively 
tested for their ability to inhibit fibril formation 
in vitro
6
. Here, we docked ligand myricetin and 
α-synuclein and analyzed for synthesizing possible 
therapeutic drug for the treatment of PD.  
Materials and Methods 
Molecular docking studies of myricetin and -synuclein fibrils 
[6FLT] 
The rigid molecular docking studies were performed 
using HEX 8.0.0 software
7
, which is an interactive 
molecular graphics program for calculating and 
displaying feasible docking modes of pairs of protein, 
enzymes and DNA molecule. The structure of the 
ligand Myricetin was sketched by CHEMSKETCH 
(http://www.acdlabs.com) and converted to pdb 
format from mol format by OPENBABEL (http:// 
www.vcclab.org/lab/babel/). The crystal structure of 
the -synuclein fibrils (protein) [PDB ID: 6FLT] 
was downloaded from the protein data bank 
(http://www.rcsb.org./pdb). It consists of chains (A, B, 
C, D, E, F, G, H, I, J) having sequence length of 121 
which is found in Homo sapiens. Visualization of 
the docked pose was done using CHIMERA 
(www.cgl.ucsf.edu/chimera) and PyMol (http://pymol. 








Drosophila culture and crosses 
The flies were cultured on standard Drosophila 
food containing agar, corn meal, sugar and yeast at 
25°C
8,9
. Crosses were set up using six virgin females 
of UAS-Hsap/SNCA.F5B and mated to three males of 
GAL4-elav. The progeny expressed human αS in the 
neurons and the flies were referred as PD flies
10
. The 
PD flies were exposed to 10, 20 and 40 µM of 
myricetin mixed in the culture medium for 24 days. 
As negative control, the PD flies were allowed to feed 
on the diet supplemented with 10
-3
 M of L-dopamine. 
The control flies (UAS-Hsap/SNCA.F) were also 
exposed to the doses 10, 20 and 40 µM of myricetin. 
Drosophila is a well established research model that 
does not require ethical clearance. 
 
Open-field assay 
Open-field assay (OFA) was performed according 
to the method described by Hirth
11
. Accordingly, 
three flies from each group were kept in an arena 
divided by squares (1 cm X 1 cm) measuring 9 cm of 
diameter, which can be covered by Petri dish.  
The number of squares crossed by each fly, during a 
given time-window (30 s), was counted. The values 




The assay was performed by the method of  
Nichols et al.
12
. Newly eclosed virgin male and 
female flies (PD and Control) were separated and kept 
in different diet vials for 24 days at 25°C under  
12 h light/dark. On the day of experiment one pair 
was transferred into a mating chamber and observed. 
Observations were made till successful copulation 
noting the time of each behavior (orientation, male 
song, chasing and licking) and the total time of 
courtship behaviors until mating. The courtship index 
(C.I.) was calculated by dividing the time of courtship 
by the total time until copulation. 
 
Odor choice index 
The assay was performed by the method of 
Simonnet et al.
13
. The test flies were starved for 16-18 h 
at 25°C before the experiment. Two small filters 
paper dipped in propionic acid and distilled water, 
respectively, were kept in the two tubes of the Y maze. 
The number of flies entering both the tubes was 
counted. Five replicates per group and 20 flies per 
group were used in the assay. The odor choice index 
(OCI) was calculated as:  
OCI= Number of flies in tube1- Number of flies in 
tube 2)/Total number of flies 
Statistical analysis 
The statistical analysis was done by performing 
one-way ANOVA using SPSS 16 and the level of 
significance was kept at P <0.05. 
 
Results  
Atomic resolution structure and cavities of  
-synuclein are illustrated in Fig. 1 (A and B). The 
docked model of ligand and protein is illustrated in 
Fig. 2. One can observe that the ligand myricetin 
snugly fits into the energetically favoured pose into 
the curved contour of the coil of 6FLT exhibiting 
proper interaction of ligand and protein as shown 
through various docked pose in Fig. 3 (A and B). 
Spherical and stick representation of docked ligand 
and protein is shown in Fig. 4. Hydrogen bonding, 
energy and hydrophobic interactions between ligand 
and protein for various conformations of docked pose 
were analyzed as illustrated in Fig. 5. The results of 
molecular docking revealed that the drug binds 
efficiently with the protein receptor and exhibit free 
energy of binding (FEB) values of -283.76 kcal mol
-1
. 
The ligand exhibited stabilization through 
hydrophobic and Vander Waals interactions with 
nearby nucleotides as illustrated in Table 1. The 
 
 
Fig. 1 — (A) Atomic resolution structure of -synuclein  




Fig. 2 — Docking of flavonoid myricetin with alpha-synuclein 
(6FLT) resulting in docked model 




hydrogen bonds and Vander Waals interactions can be 
witnessed between ligand and protein residue as 
glycine (GLY 73.I HA2∙∙∙1.het O 14.752) binds to 
oxygen of the flavonoid myricetin and (GLY 73.I 
C∙∙∙1.het C 14.266) shows interaction between  
C to carbon of the myricetin. Likewise, many 
intermolecular and intramolecular noncovalent 
interactions were observed in the protein-flavonoid 
docked model. Few such interactions are seen 
between protein residue threonine, (an amino acid) 
binds to oxygen of the myricetin (THR 75.I 
HG1∙∙∙1.het O 13.410) through its HG1 residue, 
another residue of threonine binds through its HG21 
to ligand hydrogen (THR 59.A HG21∙∙∙1.het C 7.718), 
while another threonine (THR 72.I HB∙∙∙1.het H 
16.693) bind to hydrogen of ligand through its HB 
residue. Similarly, (THR 59. A C∙∙∙1.het O 8.541) this 
threonine residue bind through C residue to carbon of 
the myricetin and another oxygen of the ligand  
is bound to HG22 of the threonine as (THR 75.I 
HG22∙∙∙1.het O 13.349). Another amino acid, 
glutamic acid has its bond with the flavonoid through 
its hydrogen part (GLU 61.C OE1∙∙∙1.het H 4.934). 
Other H-bonds and noncovalent interactions are seen 
between amino acid alanine as (ALA 56.A N∙∙∙1.het O 
10.858) through its N to oxygen of myricetin and 
lysine (LYS 58.A H∙∙∙1.het O 15.269) shows H-bond 
H of lysine and oxygen of flavonoid myricetin. 
Amongst the distances depicted here, threonine, 
lysine and glycine have the longest noncovalent 
interactions while the shortest is depicted through 
glutamic acid. Threonine is seen to possess all types 
of noncovalent interactions short and long range both. 
The H-bonds and noncovalent interactions are 
depicted in Table 1. Apart from these there are 
numerous interactions which are present between the 
docked flavonoid and 6FLT protein. 
 
A significant reduction in the activity of 8.37 fold 
was observed in PD flies compared to control flies 
(Fig. 6A; P <0.05). The flies exposed to 10, 20 and  
40 µM of myricetin showed a dose dependent significant 
increase of 2, 2.25 and 3.31 folds in the activity 
compared to PD flies (Fig. 6A; P <0.05). The PD flies 
exposed to 10
-3
 M of dopamine showed a significant 
increase of 7.93 fold in the activity compared to PD 
flies (Fig. 6A; P <0.05). The PD flies showed a 
reduction of 2.19 fold in CI compared to control flies 
(Fig. 6B; P <0.05). The PD flies exposed to 10, 20 
and 40 µM of myricetin showed a significant increase 
of 1.23, 1.33 and 1.47 folds in CI compared to 
unexposed PD flies (Fig. 6B; P <0.05). The PD flies 
exposed to 10
-3
 M of L-dopa showed a significant 
increase of 2.16 fold in CI compared to PD flies  
(Fig. 6B; P <0.05). The PD flies showed a significant 
 
 





Fig. 4 — Sphere representation of docked ligand-protein and stick 




Fig. 5 — Various non-covalent interactions and H-bonding 
exhibited by docked complex 
 
Table 1 — H-bonds and non-covalent interactions between 
amino acid residue and myricetin 
ATOM 1 ATOM 2 Distance (Å) 
GLY 73.I HA2 1.het O 14.752 
THR 75.I HG1 1.het O 13.410 
GLU 61.C OE1 1.het H 4.934 
THR 59.A HG21 1.het C 7.718 
ALA 56.A N 1.het O 10.858 
LYS 58.A H 1.het H 15.269 
THR 72.I HB 1.het H 16.693 
THR 59.A C 1.het O 8.541 
GLY 73.I C 1.het C 14.266 
THR 75.I HG22 1.het O 13.349 
 




decrease of 16.8 fold in OCI compared to control flies 
(Fig. 6C; P <0.05). The PD flies exposed to 10, 20 
and 40 µM of myricetin showed a significant increase 
of 2.4, 3.6 and 5.2 folds in OCI compared to 
unexposed PD flies (Fig. 6C; P <0.05). The PD flies 
exposed to 10
-3
 M of L-dopa showed a significant 
increase of 16 folds in OCI compared to unexposed 
PD flies (Fig. 6C; P <0.05).  
 
Discussion 
The results of the present study reveal that the 
exposure of PD flies to myricetin prevents the loss of 
cognitive impairments. In our earlier study, the 
exposure of myricetin to PD flies delayed the loss of 
climbing ability of the PD flies (expressing human  
-synuclein in the brain)
14
. In open field assay, the 
PD flies exposed to myricetin showed improved 
activity compared to the unexposed PD flies.  
Dopamine signaling in Drosophila has been shown 
to mediate voluntary movements besides other 
functions
10
. Dopamine in Drosophila is synthesized in 
a similar way as in mammals by the action of tyrosine 
hydroxylase on tyrosine
15
. In our earlier study, 
myricetin showed the protective effect against the loss 
of dopaminergic neurons. The antioxidant potential of 
myricetin was attributed for its protective effect
16
. 
This protection results in maintaining the dopamine 





The effect of PD on sexual behaviour has not been 
properly understood. Hence, we decided to study the 
effect of myricetin on Coutship Index (CI) exhibited 
by PD flies. Several neuromodulators such as 
dopamine and serotonin regulates the male sexual 
behaviour in mammals and in Drosophila dopamine 
has been reported to enhance mating
17,18
. In our study, 
the PD flies showed a significant decline in the CI, 
this is due to the loss of dopaminergic neurons 
responsible for producing dopamine. A reduction in 
the dopaminergic neurons seems to be responsible for 
the reduction in CI. The exposure of myricetin to PD 
flies results in an increase in CI which supports the 
protection of dopaminergic neurons by the myricetin. 
PD patients are reported to have olfactory deficits and 
the olfactory impairment gets severe as the disease 
progresses
19
. Olfactory impairments have been 
considered as one of the earlier non-motor traits of 
PD
20
. Dopaminergic neurons are involved in different 
types of signaling necessary for olfaction
21
. It has 
been suggested that calyx is involved in the process of 
odour learning in Drosophila
22
. A number of in vitro 
and in vitro studies suggested that the dopaminergic 
neurons in the olfactory bulb are involved in 
modulating information and behavioural odour 
discrimination. It has been reported that flavonoids 
are concentrated in the brain and activate ERk-CREB 
and Akt-CREB mediated memory, and thus could 
play a promising role for enhancing memory
24
.  
The inhibition of tyrosine hydroxylase by thimerosal 
leads decreased dopamine level which in turn causes 
dopamine related behavioural alterations in 
Drosophila melanogaster. The flies showed reduced 
locomotion, climbing ability and increased oxidative 
stress
25
. In our study, PD flies exposed to myricetin 
showed dose dependent increase in OCI. This is 
possibly due to the protection of dopaminergic 
neurons by myricetin as is evident by our earlier 
published work
16
. These transgenic flies mimicked the 
cognitive impairments associated with the PD, hence 
any improvement in the cognitive impairment after 
 
 
Fig. 6 — Effect of myricetin on (A) locomotor activity by open-field assay; (B) courtship behaviour; and (C) odour choice index in flies 
of various treated groups. The flies were allowed to feed on the diet supplemented with myricetin for 24 days. [asignificant at P <0.05 
compared to control; bsignificant at P <0.05 compared to PD flies; M= myricetin; PD= PD flies; NC=L-Dopa= 10-3M] 
 




being exposed to flavonoids (in the present study 
myricetin) supports its therapeutic effects against the 
PD symptoms.  
 
PD is also characterized by inflammation 
mitochondrial dysfunction, iron accumulation and 
oxidative stress. In the present fly model based on 
Gal4-UAS system, the human -synuclein is 
expressed and leads to the formation of Lewy bodies 
(LBs) resulting in the death of dopaminergic neurons. 
A number of natural plant products have been 
reported to curtail the progression of the disease either 
by reducing the oxidative stress or by providing a 
protection against the damage of dopaminergic 
neurons
26-29
. The neuroprotective effects of natural 
plant products have been attributed to the inhibition of 
monoamine oxidases and to modulate the content of 
neurotransmitters such as dopamine, norepinephrine 




Besides having the antioxidant potential and free 
radical scavenging activity, number of flavonoids can 
also interact with α-synuclein and inhibit α-synuclein 
fibrillation
31,32
. The pathogenesis of PD involves the 
propensity for αS to aggregate and form fibrils  
which leads to the formation of LBs which further 
damage the dopaminergic neurons
33
. Caruna et al.
34
 
have studied the effects of 14 phenolic compounds 
including myricetin on the inhibition of αS 
aggregation oligomers as well as disaggregation. They 
found that the compounds were effective in reducing 
the formation of αS aggregates as well as 
disaggregates already formed oligomers. Myricetin 
has been reported as one of the most promising agents 
against the post ischemic brain neurodegeneration  
due to its powerful antioxidant and antifibrillary 
tangles
35,36
. Zhu et al.
27
 have shown that baicalein not 
only inhibits the formation of α-synuclein fibrils but 
also disaggregates the existing fibrils. Myricetin has 
shown antifibrillogenic and fibril destabilizing effects 




Molecular docking has proved to be an important 
tool to computationally/theoretically calculate and 
rationalize the design and various conformations of 
upcoming chemotherapeutic drugs. The design of 
molecules that can recognize specific sequences and 
structures of nucleic acids plays an important role 
both for understanding nucleic acid molecular 
recognition. Interaction between myricetin and  
-synuclein fibrils (6FLT), were taken into 
consideration to study the possible docking modes 
between the flavonoid and the protein. In order to 
investigate its pharmaceutical significance, myricetin 
was docked with 6FLT and various interactions were 
explored. The positive interaction between myricetin 
and -synuclein suggests that it is potent in 
inhibiting the aggregation of -synuclein. The 
molecular structural requirements that appear 
necessary to provide a flavonoid the ability to inhibit 
-synuclein fibrillation were determined to be a 
vicinal dihydroxy-phenyl moiety
1
. The presence of 
this moiety suggests that the myricetin was effective 
in inhibiting the -synuclein fibrillation. This is also 
supported by docking studies and the interaction 
between myricetin and -synuclein exhibit free 
energy of binding value of -283.76 kcal mol
-1
. It has 
been reported that physiological concentration of  
αS is about 1 μM in normal human brain and  
70 pM in cerebrospinal fluid
38
. The concentration  





Most of the flavonoids are able to cross blood brain 
barrier (BBB) and the protective effect is attributed to 
their antioxidant potential due to the presence of 
aromatic ring by which they can performing chelating 
action. The study on rats showed that myricetin 
reduced the toxic effects of 6-OHDA in the substantia 
nigra due to reduction in the oxidative stress via  
iron chelating properties
40
. The extract of Bacopa 
monnieri and Mucuna pruriens (having myrecitin as 
one of the component) showed a significant increase 
in spontaneous locomotor activity and grip strength 
test in MPTP model of PD
41
. Myrecitin exert 
neuroprotective effect in Drosophila exposed to 
rotenone by reducing oxidative stress, protecting the 
loss of dopaminergic neurons and by improving the 





The results of our present study showed that the 
myricetin interact with α-synuclein and forms 
energetically favoured complex which may be 
helpful in reducing the formation of αS aggregates 
thereby preventing the formation of Lewy bodies 
(LBs). It also reduced the cognitive impairments 
which may also be attributed to the neuroprotective 
property of myricetin as it is a powerful antioxidant. 
Overall, our results here have shown that  
myricetin is effective in reducing the cognitive 
impairments exhibited in transgenic Drosophila 
model of PD. 
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